Questions about possible clinical scenarios for treating rheumatoid arthritis in Brazil, considering safety, effectiveness, and cost. | |
Question 1: Should the first line of treatment be csDMARD (methotrexate, hydroxychloroquine, leflunomide, or sulfasalazine), tsDMARD (tofacitinib), or bDMARD (adalimumab, certolizumab, etanercept, infliximab, golimumab, abatacept, rituximab, or tocilizumab)? | |
Question 2: Is there evidence that a particular csDMARD is more effective than other csDMARDs? | |
Question 3: Is there evidence that the use of combination therapy with two or more csDMARDs is more effective than csDMARD monotherapy as the first line of treatment? | |
Question 4: Is there evidence that after failure of a csDMARD monotherapy as the first line of treatment, the best option is to switch to a second monotherapy regimen rather than using combination therapy with two or more csDMARDs? | |
Question 5: Is there evidence that a particular TNFi (adalimumab, certolizumab, etanercept, golimumab, or infliximab) or non-TNFi (abatacept, rituximab, or tocilizumab) bDMARD is more effective than other biological agents? | |
Question 6: Is there evidence that bDMARD (adalimumab, certolizumab, etanercept, golimumab, infliximab, abatacept, rituximab, or tocilizumab) combined with methotrexate is more effective than bDMARD monotherapy? | |
Question 7: In the case of failure of a first bDMARD scheme, is there evidence that a second bDMARD scheme is effective? | |
Question 8: Is there evidence that tsDMARD (tofacitinib) is more effective than bDMARD (adalimumab, certolizumab, etanercept, golimumab, infliximab, abatacept, rituximab, or tocilizumab)? | |
Question 9: Is there evidence that oral, parenteral, or intra-articular use of corticosteroids improves prognosis when combined with DMARD? | |
Question 10: Is there evidence that it is possible to reduce the dose or increase the dose intervals for bDMARD in patients in remission? |